Several specific cytogenetic changes are known to be associated with childhood acute lymphoblastic leukemia (ALL), and many of them are important prognostic factors for the disease. Little is known, however, about the changes in gene expression in ALL. Recently, the development of cDNA array technology has enabled the study of expression of hundreds to thousands of genes in a single experiment. We used the cDNA array method to study the gene expression profiles of 17 children with precursor-B ALL. Normal B cells from adenoids were used as reference material. We discuss the 25 genes that were most over-expressed compared to the reference. These included four genes that are normally expressed only in the myeloid lineages of the hematopoietic cells: RNASE2, GCSFR, PRTN3 and CLC. We also detected over-expression of S100A12, expressed in nerve cells but also in myeloid cells. In addition to the myeloid-specific genes, other over-expressed genes included AML1, LCP2 and FGF6. In conclusion, our study revealed novel information about gene expression in childhood ALL. The data obtained may contribute to further studies of the pathogenesis and prognosis of childhood ALL.
Introduction
Cytogenetic changes are important prognostic markers in childhood acute lymphoblastic leukemia (ALL). For example, the translocation t(12;21)/ETV6-AML1 is a marker of favorable prognosis and most patients with this abnormality are best treated with conventional chemotherapy. In contrast, patients with t(4;11)/MLL-MLLT2 and t(9;22)/BCR-ABL have a poor prognosis, and high-dose chemotherapy with bone marrow transplantation is advocated (for review see Ma et al 1 ) . Despite the extensive knowledge about chromosomal abnormalities in ALL, little is known about the changes in gene expression in the disease.
In addition to genetic markers, the prognostic tools in childhood ALL include white blood cell count (WBC) at diagnosis, age, gender, CNS/testicular involvement, response to primary therapy and the phenotype of the blasts (mature B cell vs T cell vs precursor-B cell ALL). Groups of patients stratified using the existing criteria remain, however, heterogeneous and result in patients remaining in first complete remission and those relapsing either on or off therapy. 2 A more comprehensive analysis of blast cell gene expression could provide us with novel prognostic tools as well as new insight into the pathogenesis of childhood ALL.
The cDNA array methodology allows the expression levels of hundreds to thousands of genes to be evaluated in a single experiment, and the screening of genes with over-or underexpression. The method can be used to search for novel molecular changes that are associated with the development and/or prognosis of leukemia. In this study we used cDNA arrays to study gene expression profiles in the leukemic blast cells of 17 children with precursor-B ALL.
Materials and methods

Patients
A total of 17 patients (6/11, M/F) with ALL were included in the study. Fourteen patients were analyzed at diagnosis and three at relapse. Table 1 shows the key clinical data and the karyotypes of the patients. The mean age of the children was 5.0 years (range 1.2-12.7 years) and the mean WBC was 38.6 × 10 9 /l (range 1.2-272.4 × 10 9 /l). All patients had an early precursor-B phenotype, except patient 8, who had a precursor-B disease. In 16 of the 17 cases the blast population expressed the CD34 antigen, in 10 cases in conjunction with the expression of the myeloid antigens CD13 and CD33. Only in patient 8 was the blast cell population devoid of the expression of both CD34 and CD13/33. The patients were divided into standard, intermediate, and high-risk categories and treated according to the protocols of the Nordic Society of Pediatric Hematology and Oncology (NOPHO). 3 Two of the patients analyzed at primary diagnosis have relapsed, but 12 continue in first remission, one after allogeneic bone marrow transplantation from an unrelated donor. All three patients studied at relapse have received a bone marrow transplant, two from an unrelated donor and one from a matched sibling. One of the three has died following a post-transplant relapse, but two remain in second complete remission.
Samples
Whole bone marrow specimens were diluted 1:10 in RNA/DNA stabilization reagent for blood/bone marrow (Boehringer Mannheim, Mannheim, Germany) for simultaneous cell lysis and stabilization of nucleic acids. The samples were stored at −70°C until RNA isolation.
Reference material
Two separate pools of CD19-positive B cells from human adenoid samples from healthy children were used as reference material. One pool was from six individuals and the other from five. The B cells were purified using microbeads conju- gated to a monoclonal CD19 antibody (Miltenyi Biotec, Bergisch Gladbach, Germany). CD19 is expressed from earliest recognizable B-lineage cells to activated B cell blasts, but expression is lost on maturation to plasma cells. The proportion of T lymphocytes was analyzed in one of the pools, and it was less than 5%, indicating that 95% of the isolated cells were B lymphocytes.
Total RNA extraction
Nucleic acids were extracted using an mRNA isolation kit (Boehringer Mannheim) and following steps 1-6 in the manufacturer's instructions. The DNA was removed according to Clontech's (Palo Alto, CA, USA) protocol for DNase treatment of total RNA, with the exception that RNA precipitation was carried out overnight at −70°C. The quality of the total RNA was checked by gel electrophoresis. The RNA was stored at −70°C until used.
Atlas Human Hematology/Immunology cDNA array
The study was performed using Atlas Human Hematology/ Immunology cDNA expression arrays (Clontech). Each array contains duplicate cDNA spots of 415 known and sequenceverified genes, which have been found to be expressed in normal hematopoietic cells, hematopoietic cell lines, or hematological disorders (for information about the genes, see http://atlasinfo.clontech.com/bioinfo/). The cDNA spots are immobilized on a nylon membrane.
cDNA array hybridization
Total RNA (3-4 g) was converted into cDNA and labeled with 33 P-dATP using the Atlas pure total RNA labeling system (Clontech) according to the manufacturer's instructions. Probes were purified and hybridized to the arrays according to the manufacturer's instructions. The arrays were exposed to an imaging plate (BAS-MP 2040S; Fuji, Kanagawa, Japan) for 3-7 days followed by scanning of the plate with a phosphorimager (Bio-Imaging Analyzer, BAS-2500; Fuji). Two separate reference hybridizations were performed from the two distinct pools of B cells.
Quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR)
In order to validate the cDNA array results, real-time RT-PCR was performed on seven genes over-expressed in the array (ERG, AML1, ENG, ETV6, MLLT2, DAPK1 and MYC) and on one that was under-expressed (BAX). The real-time RT-PCR was only performed on samples from 15 patients because not enough RNA was available from the other two. From each patient sample and from one of the B cell pools (reference), 500 ng RNA was converted into cDNA using the first strand cDNA synthesis kit for RT-PCR (AMV) (Roche Diagnostics, Indianapolis, IN, USA). Oligo-p(dT) 15 primer was used. RTPCRs were performed simultaneously for all the samples in order to minimize variation in the amount and quality of cDNA between the samples.
The real-time PCR was performed in a rapid thermal cycler system (LightCycler; Roche Diagnostics, Mannheim, Germany). The primers were designed and prepared by TIB Molbiol (Berlin, Germany) ( Table 2 ). The PCRs were performed in a 10 l volume with 1 l 'Hot Start' reaction mix from the LightCycler-FastStart DNA Master SYBR Green I kit (Roche Diagnostics), 2.6 mM MgCl 2 , 0.5 mM each primer (0.25 mM in the case of MYC gene), and 1 l of diluted cDNA (1:5, 1:10 or 1:50; Table 2 ).
The LightCycler run was started with an initial denaturation at 95°C for 7 min. The target DNA was amplified by performing 45 cycles of denaturation at 95°C for 15 s, annealing at 58-66°C for 5 s (Table 2) , and elongation at 72°C for 10 s. To verify the amplification specificity, melting curve analyses were performed using an initial denaturation at 95°C for 10 s, followed by 20 s at 55°C, and then slow heating of the samples to 95°C at the rate of 0.1°C/s with continuous fluorescence detection.
Each patient sample was run in parallel with the reference B cell sample. A negative control without cDNA was included in each run. In addition, standard curves to calculate the relative concentrations were obtained by running a dilution series of the ␤ globin gene (LightCycler-Control Kit DNA; Roche Diagnostics) in each assay according to the manufacturer's instructions. The Second Derivative Maximum method provided by LightCycler software was used to calculate the concentration values for the PCR product of each sample.
Data analysis
cDNA array analysis
The brightness of the hybridization images was reduced so that the level of background intensity was approximately the same in all images. Then, the intensities of the gene spots were obtained using the Atlas Image 1.5 software (Clontech). The intensity of each spot on the patient array was compared with the intensity of the corresponding spot in the reference array. First, the background intensity of the hybridization image was subtracted from all intensity values. Then, the intensity of each gene spot in the reference array was subtracted from the corresponding intensity in the patient array to get the intensity difference to represent the difference in the expression of a given gene between the patient sample and the reference. The data were globally normalized by subtracting the average of the intensity differences of the genes in one array from each intensity difference value. This standardizes the sample average in all arrays to zero. In addition, the variance was standardized to one by dividing each of the normalized intensity differences of an array by the standard deviation.
Principal component analysis (PCA) was applied to normalized differences. 4 By projecting the data on the first princi- Leukemia pal component, each gene is given a score, which represents the collective difference in its expression between the patient samples and the reference. In order to assign abnormalities in gene expression to individual patients, we used lower and upper thresholds to determine under-and over-expression, respectively. We obtained these thresholds by calculating the10th and 90th percentiles of the pooled expression arrays. On the scale of normalized intensity differences, these thresholds were −5555 and 4005 for under-and over-expression, respectively.
The effect of myeloid cells on the cDNA array results
We wanted to confirm that the over-expression of five myeloid-specific genes, S100A12, RNASE2, GCSFR, PRTN3 and CLC, was not caused by the myeloid cells in the samples. In order to do this, we studied whether the proportion of myeloid cells had a non-random effect on the expression levels of these genes. The patients were divided into two groups according to the proportion of myeloid cells in their bone marrow samples, six patients with Ն10% of myeloid cells to one group, and the remaining 11 with Ͻ10% to another group (Table 1) . To test the degree of accuracy with which gene expression could predict the group assignment, we calculated the receiver operating characteristic (ROC) curve and the area under it. 5, 6 To check whether this diagnostic accuracy is statistically significant, we performed a randomization experiment by randomly permuting the group assignment and repeating the original calculation for the diagnostic accuracy 10 000 times. 7 
Comparison between the results of cDNA array and real-time RT-PCR
From the real-time RT-PCR results, the logarithm of the ratio between the patient and the reference concentrations for each gene was calculated. Similarly, for the cDNA array results, the logarithm of the ratio between the patient and the reference intensities for each gene was calculated. The logarithmic PCR ratios were plotted against the corresponding logarithmic array ratios.
Results
Over-and under-expressed genes
PCA was used to give each of the 415 genes in the array a score according to differences in expression between the patient and the reference samples. The genes with the highest and lowest scores were considered to be over-and underexpressed, respectively (Figure 1 ). On the basis of PCA projection, 25 genes (6%; marked in Figure 1 ) ranked as the most over-expressed ones compared to the reference, were chosen for detailed analysis. Table 3 lists these genes, their functions, and the type of hematopoietic cells in which they are normally expressed. The expression pattern of these genes in all the patients is shown in Figure 2 . Table 3 also shows for each gene the number of patients in whom it was over-expressed, ranging from seven to 17 patients. Among the 25 most overexpressed were genes encoding myeloid-specific proteins (RNASE2, GCSFR, PRTN3 and CLC), neuropeptide also expressed in myeloid cells (S100A12), proteins involved in the rearrangement of immunoglobulin genes (TDT and RAG1), cell surface proteins of B cell precursors (CD34, SPN, CD9 and CALLA), transcription factors (ERG, AML1, ETV6, MLLT2, MLLT1 and MYC), adapter protein (LCP2), and fibroblast growth factor (FGF6). Table 4 lists the 20 most under-expressed genes. Most of these genes are known to be expressed in mature B cells, some of them also during normal B cell development.
Confirmation of the results
The results obtained from the cDNA arrays were validated by real-time RT-PCR for seven of the over-expressed genes (ERG, AML1, ENG, ETV6, MLLT2, DAPK1, and MYC) and for one under-expressed gene (BAX). Figure 3 shows the relationship between the cDNA array and the real-time RT-PCR results for seven of the genes for which PCR was performed. ERG was not expressed in the reference sample at all, and it was excluded from the figure because the PCR concentrations could not be calculated. For most of the over-expressed genes, PCR gave much higher ratios than the cDNA array, probably because of the higher sensitivity of the method. Of the results with over-expression in the arrays (normalized intensity difference Ͼ4005), 99.7% were confirmed by PCR (ie the logarith-
Figure 1
Projection of gene expression scores calculated by principal component analysis. The scores are sorted in ascending order for the 415 genes in the array. Under-expressed genes are on the left hand side of the figure and over-expressed genes on the right. The dashed vertical line marks the limit of the 25 most over-expressed genes that were chosen for more detailed analysis. mic PCR ratio was positive). Accordingly, the PCR results agreed well with the cDNA array results.
Figure 2
Gene expression profiles of the 25 most over-expressed genes in the 17 patients. Patient numbers are at the top. The more intense the red color, the higher is the over-expression. The figures on the color scale refer to the normalized intensity differences (see Methods, Data analysis, cDNA array analysis).
Figure 3
Correspondence between the cDNA array results and the real-time RT-PCR results for seven genes in 15 patients. The ratios of patient to reference concentrations from the PCRs (y-axis) are plotted against the ratios of patient to reference intensities in the arrays (xaxis). Both ratios are on logarithmic scales. The cases for which there is correspondence appear in the upper-right quadrant (over-expression) and the lower-left quadrant (under-expression). 
Exclusion of the effect of myeloid cells
Because the patient samples were from whole bone marrow, we wanted to find out whether the over-expression of myeloid-specific genes was caused by the presence of myeloid cells in the samples. We focused on those of the 25 most over-expressed genes that are normally expressed in myeloid cells but not in B lymphoid cells, ie S100A12, RNASE2, GCSFR, PRTN3 and CLC.
The ROC values for the genes ranged from 0.286 to 0.657 and the P values from 0.134 to 0.457. Thus, we were unable to demonstrate a statistically significant non-random effect between the proportion of myeloid cells and the expression of any of the five genes. We concluded that the small amount of myeloid cells did not have a significant effect on the expression level seen in the myeloid-specific genes.
Discussion
In this study we performed gene expression analysis by cDNA arrays comparing gene expression of leukemic blasts to normal mature B cells. Recently, the authors of an extensive gene expression profiling study performed gene clustering analyses but they did not compare expression of leukemic cells to any references. 8 Thus their results cannot be compared to ours.
Out of the 20 most under-expressed genes, at least 16, including LCP1, CD83, LYN, SPIB and CD48, are known to be expressed in mature B cells. [9] [10] [11] [12] [13] Although some of the underexpressed genes are also known to be expressed during the development of B cells, the under-expression of most of them may be a consequence of the use of mature B cells as reference for the precursor-B cell type of leukemia. Thus, we focused our more detailed analysis on the 25 most over-expressed genes.
Four of the 25 most over-expressed genes that are usually considered to be expressed specifically in the myeloid lineage: GCSFR, PRTN3, RNASE2 and CLC.
14-17 Since we compared whole bone marrow to a B cell reference, it was possible that the over-expression originated from the myeloid cells in the patient samples. However, by calculating an area under a ROC curve and performing a randomization experiment, we showed that the small amount of myeloid cells (1-15%) did not affect the results. Thus, we conclude the over-expression of these myeloid genes to be a consequence of their up-regulation in the leukemic blasts.
Variable degrees of phenotypic expression of myeloid markers can be detected in many cases with B-lineage ALL using flow cytometry. 18 The same was found in our immunophenotype studies, in which the blast population showed expression of CD34 and CD13 antigens in 16 and 10 patients, respectively. Importantly, our array studies showed over-expression of CD34 and CD13 in 15 and six patients, respectively.
Two of the myeloid-specific genes, GCSFR and PRTN3, encode proteins that are known to regulate cell proliferation, their over-expression thus possibly having some role in leukemogenesis. GCSFR encodes the receptor for G-CSF, a myeloid growth factor. 19 GCSFR has been found to be up-regulated in precursor-B ALL by the t(1;19)-specific oncoprotein E2A-PBX1. 20 Only one patient (patient 16) with this translocation was included in our study. This patient was one of several patients with over-expression of GCSFR, suggesting that the up-regulation of GCSFR is not restricted to patients with t(1;19). PRTN3 is a gene known to be up-regulated by G-CSF. 21 The PRTN3 protein is a serine protease involved in the regulation of cell growth and differentiation, and the constitutive over-expression of the gene causes G-CSF-independent growth of myeloid progenitors, the G-CSF receptor being essential for this process. 15, 21 Involvement of PRTN3 in ALL has not been reported before.
In addition to 'true' myeloid-specific genes, we detected over-expression of the gene encoding neuropeptide S100A12 which, in addition to being released from sensory nerve endings to the bone marrow, is known to be synthesized in myeloid cells. [22] [23] [24] The S100A12 protein has numerous functions, one of which is to inhibit B cell development. 25 We previously also found over-expression of S100A12 in CLL using arrays. 26 This gene has not been associated with ALL before.
By using mature B cells as the reference for precursor-B cell ALL, over-expression was likely to be detected in those genes that are distinctly more highly expressed in the early stages of B cell development. In agreement with this, we found overexpression of the genes involved in the rearrangement of immunoglobulin genes (TDT and RAG1) and the genes encoding surface proteins known to be expressed only during the early stages of lymphoid differentiation (CD34, SPN, CD9 and CALLA) (see Table 3 for functions). In addition, expression of murine homologues of ERG, ETV6 and MLLT2 is higher in B cell precursors than in mature B cells. 27, 28 These genes encode transcription factors, which are known to be involved in the recurrent translocations found in acute leukemias, ERG in t(16;21)(p11;q22), ETV6 in t(12;21)(p13;q22), and MLLT2 in t(4;11)(q21;q23). [29] [30] [31] For these genes, all or at least most of the over-expression detected is probably related to differentiation.
The over-expression of the well-known proto-oncogene MYC would be expected given that MYC expression correlates with the stage of differentiation and the proliferative activity of B cells. 32 Yet, MYC is up-regulated by translocations in Burkitt's lymphoma and mature B cell and T cell ALL, and by amplification or other mechanisms in AML and in several solid tumors. 29, [33] [34] [35] [36] Like ETV6 (see above), its partner in the t(12;21) translocation, AML1, was found to be over-expressed. The translocation t(12;21)(p13;q22), resulting in the production of a chimeric ETV6-AML1 protein, is present in about 25% of children with B-lineage ALL. 30, 31, [37] [38] [39] The level of AML1 overexpression in our material was very high and several pieces of evidence suggest that its over-expression may cause leukemia. We previously found a high-level amplification of AML1 in two out of 112 children with ALL, and AML1 is located in chromosome 21, which is gained in about 25% of children with ALL. 40, 41 In addition, up-regulation of the gene shortens the G1 phase of the cell cycle in myeloid progenitor cells and leads to neoplastic transformation in fibroblasts. 42, 43 It has to be noted, however, that AML1 encodes a variety of alternative mRNA forms with different functions and, in addition to the Leukemia absolute amount of AML1 mRNA, the relative amounts of different transcripts are important for the proper functioning of the gene. 44, 45 Because the primers that we used recognize a number of different AML1 mRNAs, we cannot determine their individual contribution.
We also detected over-expression of LCP2, a gene encoding an adapter protein involved in precursor T and T cell receptor signaling (reviewed in Rudd 46 ). LCP2 is expressed in some B cell lines and normal splenic B cells. 47, 48 Over-expression of LCP2 has been detected in a Burkitt's lymphoma B cell line after B cell receptor cross-linking, and the protein may have a role in B cell receptor signaling as well. 48, 49 Interestingly, LCP2 was also found to be over-expressed in CLL by the cDNA array method. 26 No involvement of the gene in ALL has been reported so far. One of the most interesting findings of this study was the over-expression of a gene encoding a fibroblast growth factor, FGF6, not normally expressed in bone marrow. Expression of FGFR1 and FGFR4, encoding receptors of FGF6, has been detected in several leukemic cell lines including precursor B cells, and the expression of FGFR1 has also been detected in purified mature B cells. [50] [51] [52] The FGF6 protein in turn has been shown to up-regulate the expression of FGFR1 in myoblasts. 53 Interestingly, we found over-expression of FGFR1 in five out of the 12 patients showing over-expression of FGF6, whereas that was not detected in any patient without over-expression of FGF6. FGFR1 is involved in several 8p12 translocations leading to constitutive tyrosine kinase activity of FGFR1 in a stem cell myeloproliferative disorder that generally progresses to AML. [54] [55] [56] Furthermore, we have previously demonstrated FGFR1 overexpression in AML cases without these translocations, using cDNA arrays. 57 No association of either FGF6 or FGFR1 with ALL has been reported. In conclusion, we obtained novel data about gene expression in childhood ALL using cDNA arrays. Among the most over-expressed were several 'myeloid-specific' genes (S100A12, RNASE2, GCSFR, PRTN3 and CLC) and their over-expression was found to derive from the leukemic blasts. Other most over-expressed genes included AML1, LCP2 and FGF6. Although the use of normal B cells as a reference would pick up genes both on the basis of differentiation specificity as well as of tumor specificity, both may be important in identifying pathways for future therapeutic interventions. Further studies using more patient material and different techniques are needed to investigate which of the genes are involved in the leukemogenic process and whether any of the findings can be used as prognostic indicators for ALL.
